Immuno-suppressive peptides for a human T cell clone autoreactive to a unique acetylcholine receptor α subunit peptide presented by the disease- susceptible HLA-DQ6 in infant-onset myasthenia gravis

Human Immunology

Volumn 56, Issue 1-2, 1997, Pages 28-38

  Kanai, Takayuki ^a,c   Nomura, Yoshiko ^b   Segawa, Masaya ^b   Takagi, Katsumasa ^c   Senju, Satoru ^a   Matsushita, Sho ^a   Nishimura, Yasuharu ^a  

^a Division of Immunogenetics   (Japan)

^b Segawa Neurol Clinic for Children   (Japan)

^c KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CHOLINERGIC RECEPTOR; GAMMA INTERFERON; HLA DQ ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 4; T LYMPHOCYTE RECEPTOR;

ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; HELPER CELL; HLA TYPING; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; JAPAN; LYMPHOCYTE PROLIFERATION; MONONUCLEAR CELL; MYASTHENIA GRAVIS; PRIORITY JOURNAL;

ANTIBODIES, BLOCKING; ANTIGEN PRESENTATION; CHILD, PRESCHOOL; CLONE CELLS; EPITOPES, T-LYMPHOCYTE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-D ANTIGENS; HUMANS; IMMUNE TOLERANCE; INFANT; INFANT, NEWBORN; LYMPHOCYTE ACTIVATION; MYASTHENIA GRAVIS; PEPTIDE FRAGMENTS; PEPTIDES; RECEPTORS, CHOLINERGIC; RECOMBINANT PROTEINS; T-LYMPHOCYTES;

EID: 0031459009     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(97)00142-0     Document Type: Article

References (53)

1. Fukuyama Y, Hirayama Y, Osawa M (eds): In Japan medical research foundation Myasthenia Gravis. Pathogenesis and Treatment. Tokyo, University of Tokyo Press, 1981.
2. Simpson JA: In Watson, J. (eds): Disorders of Voluntary Muscle. London, Churchill Livingstone, 1981.
3. Naeim F, Keesey JC, Herrmann C Jr, Lindstrom J, Zeller E, Walford RL. Association of HLA-B8, DRw3, and anti-acetylcholine receptor antibodies in myasthenia gravis. Tissue Antigens. 12:1978;381.
4. Pirskanen R. On the significance of HL-A and LD antigens in myasthenia gravis. Ann NY Acad Sci. 274:1976;451.
5. Matsuki K, Juji T, Tokunaga K, Takamizawa M, Maeda H, Soda M, Nomura Y, Segawa M. HLA antigens in Japanese patients with myasthenia gravis. J Clin Invest. 86:1990;392.
6. Nomura Y, Ehara M, Matsuki K, Juji T, Segawa M. HLA haplotype in myasthenia gravis (MG) of Japanese children Correlative studies between MG patients and their normal siblings and parents . Ann NY Acad Sci. 681:1993;581.
7. Germain RN, Margulies DH. The biochemistry and cell biology of antigen processing and presentation. Annu Rev of Immunol. 11:1993;403.
8. Todd JA, Acha-Orbea H, Bell JI, Chao N, Fronek Z, Jacob CO, McDermott M, Sinha AA, Timmerman L, Steinman L, McDevitt HO. A molecular basis for MHC class II-associated autoimmunity. Science. 240:1988;1003.
9. Vyse TJ, Todd JA. Genetic analysis of autoimmune disease. Cell. 85:1996;311.
10. Raftery MA, Hunkapiller MW, Strader CD, Hood LE. Acetylcholine receptor complex of homologous subunits . Science. 208:1980;1454.
11. Beeson D, Morris A, Vincent A, Newsom-Davis J. The human muscle nicotinic acetylcholine receptor alpha-subunit exists as two isoforms a novel exon . EMBO J. 9:1990;2101.
12. Morris A, Beeson D, Jacobson L, Baggi F, Vincent A, Newsom-Davis J. Two isoforms of the muscle acetylcholine receptor alpha-subunit are translated in the human cell line TE671. FEBS Lett. 295:1991;116.
13. Engel AG. Myasthenia gravis and myasthenic syndromes. Ann Neurol. 16:1984;519.
14. Levinson AI, Zweiman B, Lisak RP. Immunopathogenesis and treatment of myasthenia gravis. J Clin Immunol. 7:1987;187.
15. Tzartos SJ, Kokla A, Walgrave SL, Conti-Tronconi BM. Localization of the main immunogenic region of human muscle acetylcholine receptor to residues 67-76 of the alpha subunit. Proc Natl Acad Sci USA. 85:1988;2899.
16. Willcox N, Baggi F, Batocchi AP, Beeson D, Harcourt G, Hawke S, Jacobson L, Matsuo H, Moody AM, Nagvekar N, Nicolle M, Ong B, Pantic N, Newson-Davis J, Vincent A. Approaches for studying the pathogenic T cells in autoimmune patients. Ann NY Acad Sci. 681:1993;219.
17. Manfredi AA, Protti MP, Dalton MW, Howard JF Jr, Conti-Tronconi BM. T helper cell recognition of muscle acetylcholine receptor in myasthenia gravis Epitopes on the gamma and delta subunits . J Clin Invest. 92:1993;1055.
18. + cells of myasthenia gravis patients and healthy subjects. J Clin Invest. 93:1994;1020.
19. + epitopes . J Immunol. 152:1994;4686.
20. Matsuo H, Batocchi AP, Hawke S, Nicolle M, Jacobson L, Vincent A, Newsom-Davis J, Willcox N. Peptide-selected T cell lines from myasthenia gravis patients and controls recognize epitopes that are not processed from whole acetylcholine receptor. J Immunol. 155:1995;3683.
21. Chen YZ, Matsushita S, Nishimura Y. Response of a human T cell clone to a large panel of altered peptide ligands carrying single residue substitutions in an antigenic peptide characterization and frequencies of TCR agonism and TCR antagonism with or without partial activation . J Immunol. 157:1996;3783.
22. Matsuoka T, Kohrogi H, Ando M, Nishimura Y, Matsushita S. Altered TCR ligands affect antigen-presenting cell responses up-regulation of IL-12 by an analogue peptide . J Immunol. 157:1996;4837.
23. Sone T, Tsukamoto K, Hirayama K, Nishimura Y, Takenouchi T, Aizawa M, Sasazuki T. Two distinct class II molecules encoded by the genes within HLA-DR subregion of HLA-Dw2 and Dw12 can act as stimulating and restriction molecules. J Immunol. 135:1985;1288.
24. Matsuoka T, Kohrogi H, Ando M, Nishimura Y, Matsushita S. Dermatophagoides farinae-1-derived peptides and HLA molecules recognized by T cells from atopic individuals. Int Arch Allergy Immunol. 112:1997;365.
25. Kasahara M, Takenouchi T, Ikeda H, Ogasawara K, Okuyama T, Ishikawa N, Wakisaka A, Kikuchi Y, Aizawa M. Serologic dissection of HLA-D specificities by the use of monoclonal antibodies II. Distinction between HLA-Dw2 and HLA-Dw12 . Immunogenetics. 18:1983;525.
26. Kimura A, Sasazuki T: In Tsuji k, Aizawa M. and Sasazuki T. (eds): HLA 1991: Proceedings of the 11th International Histocompatibility Workshop and Conference, vol. 1. Oxford, Oxford University Press, 1992.
27. Matsushita S, Takahashi K, Motoki M, Komoriya K, Ikagawa S, Nishimura Y. Allele specificity of structural requirement for peptides bound to HLA-DRB1*0405 and -DRB1*0406 complexes implication for the HLA-associated susceptibility to methimazole-induced insulin autoimmune syndrome . J Exp Med. 180:1994;873.
28. Bodmer JG, Marsh SG, Albert ED, Bodmer WF, Dupont B, Erlich HA, Mach B, Mayr WR, Parham P, Sasazuki T, Schreuder GMTh Strominger JL, Svejgaard A, Terasaki PI. Nomenclature for factors of the HLA system, 1994. Hum Immunol. 41:1994;1.
29. Protti MP, Manfredi AA, Straub C, Howard JF Jr, Conti-Tronconi BM. Immunodominant regions for T helper-cell sensitization on the human nicotinic receptor alpha subunit in myasthenia gravis. Proc Natl Acad Sci USA. 87:1990;7792.
30. + T-epitope repertoire on the human acetylcholine receptor alpha subunit in severe myasthenia gravis a study with synthetic peptides . Neurology. 42:1992;1092.
31. Oshima M, Ashizawa T, Pollack MS, Atassi MZ. Autoimmune T cell recognition of human acetylcholine receptor the sites of T cell recognition in myasthenia gravis on the extracellular part of the alpha subunit . Eur J Immunol. 20:1990;2563.
32. Brocke S, Brautbar C, Steinman L, Abramsky O, Rothbard J, Neumann D, Fuchs S, Mozes E. In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to HLA class II genes. J Clin Invest. 82:1988;1894.
33. Moiola L, Protti MP, Manfredi AA, Yuen MH, Howard JF Jr, Conti-Tronconi BM. T-helper epitopes on human nicotinic acetylcholine receptor in myasthenia gravis. Ann NY Acad Sci. 681:1993;198.
34. MacLennan C, Beeson D, Vincent A, Newsom-Davis J. Human nicotinic acetylcholine receptor alpha-subunit isoforms origins and expression . Nucleic Acids Res. 21:1993;5463.
35. Segawa M, Nomura Y, Nagata E. Myasthenia Gravis (MG) in childhood-age at onset and pathogenesis. Brain Dev. 8:1986;2.
36. Protti MP, Manfredi AA, Horton RM, Bellone M, Conti-Tronconi BM. Myasthenia gravis recognition of a human autoantigen at the molecular level . Immunol Today. 14:1993;363.
37. Link J, Soderstrom M, Ljungdahl A, Hojeberg B, Olsson T, Xu Z, Fredrikson S, Wang ZY, Link H. Organ-specific autoantigens induce interferon-gamma and interleukin-4 mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis. Neurology. 44:1994;728.
38. Willcox N. Myasthenia gravis. Curr Opin Immunol. 5:1993;910.
39. Nakano S, Engel AG. Myasthenia gravis quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients . Neurology. 43:1993;1167.
40. Zhang YP, Porter S, Wekerle H. Schwann cells and myasthenia gravis Preferential uptake of soluble and membrane-bound AChR by normal and immortalized Schwann cells, and immunogenic presentation to AChR-specific T line lymphocytes . Am J Pathol. 136:1990;111.
41. Matsushita S, Nishi T, Oiso M, Yamaoka K, Yone K, Kanai T, Nishimura Y. HLA-DQ-binding peptide motifs I. Comparative binding analysis of type II collagen-derived peptides to DR and DQ molecules of rheumatoid arthritis-susceptible and non-susceptible haplotypes . Int Immunol. 8:1996;757.
42. Kropshofer H, Vogt AB, Stern LJ, Hammerling GJ. Self-release of CLIP in peptide loading of HLA-DR molecules. Science. 270:1995;1357.
43. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity Viral peptides activate human T cell clones specific for myelin basic protein . Cell. 80:1995;695.
44. De Magistris MT, Alexander J, Coggeshall M, Altman A, Gaeta FC, Grey HM, Sette A. Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell. 68:1992;625.
45. Racioppi L, Ronchese F, Matis LA, Germain RN. Peptide-major histocompatibility complex class II complexes with mixed agonist/antagonist properties provide evidence for ligand-related differences in T cell receptor-dependent intracellular signaling. J Exp Med. 177:1993;1047.
46. Alexander J, Snoke K, Ruppert J, Sidney J, Wall M, Southwood S, Oseroff C, Arrhenius T, Gaeta FC, Colon SM, Grey HM, Sette A. Functional consequences of engagement of the T cell receptor by low affinity ligands. J Immunol. 150:1993;1.
47. Sloan-Lancaster J, Evavold BD, Allen PM. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature. 363:1993;156.
48. Sloan-Lancaster J, Evavold BD, Allen PM. Th2 cell clonal anergy as a consequence of partial activation. J Exp Med. 180:1994;1195.
49. Matsushita S, Nishimura Y. Partial activation of human T cells by peptide analogs on live APC induction of clonal anergy associated with protein tyrosine dephosphorylation . Hum Immunol. 53:1997;73.
50. Ikagawa S, Matsushita S, Chen YZ, Ishikawa T, Nishimura Y. Single amino acid substitutions on a Japanese cedar pollen allergen (Cry j 1)-derived peptide induced alterations in human T cell responses and T cell receptor antagonism. J Allergy Clin Immunol. 97:1996;53.
51. Evavold BD, Allen PM. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand. Science. 252:1991;1308.
52. Soloway P, Fish S, Passmore H, Gefter M, Coffee R, Manser T. Regulation of the immune response to peptide antigens differential induction of immediate-type hypersensitivity and T cell proliferation due to changes in either peptide structure or major histocompatibility complex haplotype . J Exp Med. 174:1991;847.
53. Matsushita S, Kohsaka H, Nishimura Y. Evidence for self- and non-self-peptide partial agonists that prolong clonal survival of mature T cells in vitro. J Immunol. 158:1997;5685.